Core Viewpoint - Heng Rui Medicine (01276.HK) has received approval from the National Medical Products Administration for clinical trials of HRS-3095 tablets, aimed at treating Chronic Spontaneous Urticaria (CSU) [1] Group 1: Clinical Trial Approval - The clinical trial approval notice for HRS-3095 was issued based on compliance with the Drug Administration Law of the People's Republic of China [1] - The application for HRS-3095 was accepted on July 7, 2025, and has met the requirements for drug registration [1] Group 2: Drug Development - HRS-3095 is a small molecule compound developed by the company that targets immune cells and shows promising therapeutic effects for allergic diseases [1] - Preclinical data indicates that HRS-3095 can effectively improve skin allergy symptoms in mice [1] - Currently, there are no approved drugs targeting the same mechanism for CSU in both domestic and international markets [1] Group 3: Research Investment - The total research and development investment for the HRS-3095 project has reached approximately 16.03 million yuan [1]